An observational study in Multiple Sclerosis, Cognitive Dysfunction and Neuropsychological Tests, sponsored by Centre Hospitalier de Gonesse. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-19.
Sponsored by Centre Hospitalier de Gonesse · Observational
This study aims to identify cognitive problems in adults with multiple sclerosis (MS). MS can affect memory, thinking speed, and spatial skills, which may impact daily life and work. We will use simple and proven tests to check for these difficulties and see how they affect quality of life. The study will include about 60 patients followed at the neurology day hospital.
3,264 studies on the registry are indexed under Multiple Sclerosis; 659 are open to participants now.
This study's planned enrollment of 60 is below the median of 100 across 970 observational studies indexed under Multiple Sclerosis.
Browse Multiple Sclerosis studies →Centre Hospitalier de Gonesse is the lead sponsor of 15 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population consists of adult patients (18 years and older) diagnosed with multiple sclerosis for at least six months according to the 2017 McDonald criteria. These patients are currently receiving disease-modifying treatments and are followed at the neurology day hospital of CH Gonesse.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Prevalence of cognitive impairment in patients with multiple sclerosis, assessed by validated cognitive tests (CSCT, RL/RI-16, Figure de REY, HAD scale, SF-12).
Time frame: 12 months
This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier de Gonesse